Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination

Author:

Ntowe Koumani W.1ORCID,McAdoo Sallie2,Haas Naomi B.3,Karam Jose A.4,Lara Primo N.5,Fashoyin-Aje Ibilola6,Saraiya Biren P.7,Maskens Deborah8,Pickering Lisa9,Master Viraj A.10,Zhang Tian11,Kaye Deborah R.1

Affiliation:

1. Department of Urology at Duke University, Durham, NC, USA

2. Kidney Cancer Association, Houston, TX, USA

3. Prostate and Kidney Cancer Program, University of Pennsylvania, Philadelphia, PA, USA

4. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5. UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

6. Oncology Center for Excellence of the Food and Drug Administration, Silver Spring, MD, USA

7. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

8. International Kidney Cancer Coalition, Duivendrecht, The Netherlands

9. The Royal Marsden, London, UK

10. Department of Urology, Emory University, Atlanta, GA, USA

11. Department of Internal Medicine, UT Southwestern Medical School, Dallas, TX, USA

Abstract

Background: Kidney cancer is amongst the deadliest genitourinary malignancies. Neoadjuvant systemic therapy has the potential to improve survival and overall outcomes in select patients. Enrolling patients in trials of neoadjuvant treatment for kidney cancer is challenging, which limits neoadjuvant treatment development. Objective: This study aims to develop a better understanding of the barriers patients face in kidney cancer clinical trial participation, with a particular focus on neoadjuvant trials for renal cell carcinoma. Methods: From 2022–2023, we recruited participants with a history of kidney cancer through a Qualtrics survey that was sent to the Kidney Cancer Association (KCA) and Kidney Cancer Cure (KCCure) mailing lists and social media pages. Patient responses on demographics, clinical information, and perspectives were evaluated. Results: Ninety-four individuals completed the survey. Eighty-one percent of respondents reported not participating in clinical trials due to not being informed about potential applicable trials. Importantly, many (76%) respondents reported that prevention of cancer return was a highly important reason to participate in clinical trials. Most respondents reported a willingness to undergo a kidney biopsy (59%), and/or additional appointments (58%) and surgery delays. Conclusions: Increased patient awareness about clinical trials with the potential to delay cancer recurrence may increase patient participation in clinical trials. Clinical trial design, including additional appointments or interventions and/or minor surgery delays are not major barriers to trial participation.

Publisher

IOS Press

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3